Research Paper Volume 14, Issue 8 pp 3597—3606
Synergistic blocking of RAS downstream signaling and epigenetic pathway in KRAS mutant pancreatic cancer
Figure 1. The MEK inhibitor trametinib suppresses KRAS mutant pancreatic cancer cells. (A) The structure of the MEK inhibitor trametinib. (B) Fitting curve of cytostatic responses illustrated a decreasing concentration gradient of trametinib in 7 KRAS mutant pancreatic cancer cell lines (AsPC-1, MIA PaCa-2, PANC-1, HuP-T4, HuP-T3, PSN1, and CFPAC-1).